Infertility Panel Centogene US, LLC - The Rare Disease Company
United States | 243 | 238 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Infertility Panel Centogene AG - the Rare Disease Company
Germany | 243 | 238 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Inheritest 500 PLUS Panel Integrated Genetics Westborough LabCorp
United States | 287 | 578 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Horizon 137 Male Natera, Inc.
United States | 130 | 133 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Horizon 14 Male plus TSE Natera, Inc.
United States | 12 | 14 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Horizon 14 Male Natera, Inc.
United States | 12 | 13 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
Horizon 274 Male Natera, Inc.
United States | 244 | 254 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
|
DHCR7 Prenatal Sequence Analysis (GeneAware) (Prenatal Sequence Analysis) Baylor Genetics
United States | 1 | 1 | - E Sequence analysis of select exons
|
Super Panel Plus NxGen MDx
United States | 116 | 117 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Super Panel 113 NxGen MDx
United States | 113 | 115 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 14 Natera, Inc.
United States | 15 | 15 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 plus TSE Natera, Inc.
United States | 103 | 107 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 27 Natera, Inc.
United States | 28 | 28 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 Natera, Inc.
United States | 103 | 106 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 27 plus TSE Natera, Inc.
United States | 28 | 29 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Plus TSE Natera, Inc.
United States | 265 | 275 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 plus TSE Natera, Inc.
United States | 135 | 138 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 Natera, Inc.
United States | 135 | 137 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
